Skip to main content

Table 3 Baseline (t0) features and JC viruria of 21 MS, 18 CIRDs and 22 CD patients

From: Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

Pathology

Cohort1 MS

Cohort2

Cohort3 CD

Control group

PsA

RA

AS

CIRDs

Female / Male

10 / 11*

5 / 6

8 / 0

2 / 1

15 / 7

8 / 10

10 / 9

JCPyV+ / JCPyV-

2 / 18*

4 / 7

7 /1

3 / 0

14 / 8

6 / 12

5 / 14

JCPyV load†

3.90 (3.70 - 4.10)

7.27 (4.23-8.09)

6.92 (4.15-8.13)

7.25 (5.08-7.68)

7.21 (4.15 - 8.13)

6.30 (4.85-8.85)

5.75 (3.54-8.43)

Age†

37 (19–49)

53 (46–72)

53.5 (36–79)

47 (38–54)

53 (36–79)

15 (8–22)

35 (25–47)

Symptoms onset, months ago†

72 (12–300)

60 (24–312)

108 (52–156)

120 (36–420)

75 (24–420)

nd ‡

 

Disease activity†§

2 (0–4)§

4.11 (2.46–4.61)§

4.18 (2.50–5,89)§

7,3 (4–10)§

 

> 30 §

 
  1. MS: multiple sclerosis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; AS: ankylosing spondylitis; CD: Crohn's disease; CIRDs: chronic inflammatory rheumatic diseases.
  2. † For each category the median values (range) are indicated. In particular JCPyV loads values are expressed as log10 genome equivalent (gEq)/mL in urine and in plasma, and as log10 gEq/106 cells in PBMCs.
  3. §: Disease Activity is indicated by scale, score or index specific for each disease assessed: for Cohort1 MS, Kurtzke Expanded Disability Status Scale (EDSS) is used. This scale ranges from 0 (normal neurological examination) to 10 (confined to bed); for PsA and RA (Cohort2), Disease Activity Score with a 28-joint count related to C-reactive protein (DAS28-CRP) is used, with a high score indicating more active disease; for AS (Cohort2), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used. This index ranges from 0 (no activity) to 10 (maximum activity); for Cohort3 CD, Pediatric Crohn's Disease Activity Index (PCDAI) is used (score ≤10: inactive disease; 10–30: mild disease; >30: moderate to severe disease).
  4. * At t0, 1 patient (out of the 21 multiple sclerosis patients enrolled) do not perform the urine and blood sampling.
  5. ‡ nd: no data.